A Phase 2 interventional study of Placebo and BMS-582949 in Vascular Diseases, sponsored by Bristol-Myers Squibb. Completed at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-12-07.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
The purpose of the study is to determine whether a p38 kinase inhibitor reduces inflammation in atherosclerotic plaque
1,027 studies on the registry are indexed under Vascular Diseases; 167 are open to participants now.
This study's enrollment of 72 is close to the median of 78 across 639 interventional studies indexed under Vascular Diseases.
Browse Vascular Diseases studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Placebo + background low to moderate dose statin Tablets, Oral, 0 mg, once daily, for 12 weeks
Other: Placebo · Drug: Statin
BMS-582949 + Background low to moderate dose statin Tablets, Oral, 100 mg, once daily for 12 weeks
Drug: BMS-582949 · Drug: Statin
Atorvastatin Tablets, oral, 80 mg once daily for 12 weeks
Drug: Atorvastatin
FDG-PET signal of the carotid and/or ascending aorta
Time frame: at 4 and 12 weeks
Inflammatory and thrombotic biomarkers
Time frame: will be measured throughout the 12 weeks of treatment
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb